Search research articles
Contact Us
Filters
Showing results (131-140 of 150) with videos related to
Page
of 15
Sort By:
Plos One
|
September 28, 2019
A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study)
Cristina Mussini, Enrica Roncaglia, Vanni Borghi, et al.
Expert Review of Anti-Infective Therapy
|
October 15, 2020
Enhancing care for people living with HIV: current and future monitoring approaches
Franco Maggiolo, Alessandra Bandera, Stefano Bonora, et al.
BMJ Open
|
February 10, 2024
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors
Tommaso Clemente, Laura Galli, Riccardo Lolatto, et al.
International Journal of Environmental Research and Public Health
|
March 11, 2023
Healthcare Resource Consumption and Related Costs in Patients on Antiretroviral Therapies: Findings from Real-World Data in Italy
Valentina Perrone, Melania Dovizio, Diego Sangiorgi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
January 25, 2020
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis
Joseph Eron, Chien-Ching Hung, Jean-Guy Baril, et al.
Antiviral Therapy
|
September 17, 2013
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting
Antonella d'Arminio Monforte, Nicola Gianotti, Alessandro Cozzi-Lepri, et al.
Antimicrobial Agents and Chemotherapy
|
January 7, 2009
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev
Valentina Svicher, Claudia Alteri, Roberta D'Arrigo, et al.
The Journal of Antimicrobial Chemotherapy
|
October 13, 2019
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study
Sara Modica, David Redi, Roberta Gagliardini, et al.
The Lancet. HIV
|
June 7, 2020
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
Chloe Orkin, Edwin DeJesus, Paul E Sax, et al.
Journal of Viral Hepatitis
|
December 11, 2020
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting
Massimiliano Fabbiani, Andrea Lombardi, Marta Colaneri, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 150) with videos related to
Sort By:
Page
of 15
Plos One
|
September 28, 2019
A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study)
Cristina Mussini, Enrica Roncaglia, Vanni Borghi, et al.
Expert Review of Anti-Infective Therapy
|
October 15, 2020
Enhancing care for people living with HIV: current and future monitoring approaches
Franco Maggiolo, Alessandra Bandera, Stefano Bonora, et al.
BMJ Open
|
February 10, 2024
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors
Tommaso Clemente, Laura Galli, Riccardo Lolatto, et al.
International Journal of Environmental Research and Public Health
|
March 11, 2023
Healthcare Resource Consumption and Related Costs in Patients on Antiretroviral Therapies: Findings from Real-World Data in Italy
Valentina Perrone, Melania Dovizio, Diego Sangiorgi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
January 25, 2020
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis
Joseph Eron, Chien-Ching Hung, Jean-Guy Baril, et al.
Antiviral Therapy
|
September 17, 2013
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting
Antonella d'Arminio Monforte, Nicola Gianotti, Alessandro Cozzi-Lepri, et al.
Antimicrobial Agents and Chemotherapy
|
January 7, 2009
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev
Valentina Svicher, Claudia Alteri, Roberta D'Arrigo, et al.
The Journal of Antimicrobial Chemotherapy
|
October 13, 2019
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study
Sara Modica, David Redi, Roberta Gagliardini, et al.
The Lancet. HIV
|
June 7, 2020
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
Chloe Orkin, Edwin DeJesus, Paul E Sax, et al.
Journal of Viral Hepatitis
|
December 11, 2020
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting
Massimiliano Fabbiani, Andrea Lombardi, Marta Colaneri, et al.
Page
of 15